Kintor Pharmaceutical (9939) Fundamentals 2026 — Revenue Analysis | SniperIQ

.71 on the HKSE. This SniperIQ fundamentals page covers Kintor Pharmaceutical's valuation, profitability (net margin -601.2%), revenue (¥33M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is Kintor Pharmaceutical's market cap?

Kintor Pharmaceutical (9939) has a market capitalization of approximately HK$802M, trading at HK

.71 on the HKSE. Market cap moves with the live share price.

What is Kintor Pharmaceutical's P/E ratio?

Kintor Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Kintor Pharmaceutical?

Kintor Pharmaceutical runs a net profit margin of -601.2%, a gross margin of 24.6%, and an operating margin of -611.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Kintor Pharmaceutical generate?

Kintor Pharmaceutical reported revenue of ¥33M for fiscal year 2025, with net income of -¥200M and earnings per share (EPS) of -0.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Kintor Pharmaceutical pay a dividend?

Kintor Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Kintor Pharmaceutical financially healthy?

Kintor Pharmaceutical carries a debt-to-equity ratio of 0.47x and a current ratio of 0.43x, with a market beta of -0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Kintor Pharmaceutical a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kintor Pharmaceutical (9939) the key facts are: market cap HK$802M, revenue ¥33M, 52-week range 1.65-4.7. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.